Assessment of antiplatelet activity of 2-aminopyrimidines
摘要:
A series of 4,6-diaryl-2-aminopyrimidines was developed as antiplatelet agents and their potency was evaluated by in vitro assay. Compound 14k was found to be two times more potent than aspirin. These encouraging results could be helpful for the development of new antiplatelet compounds. (C) 2012 Elsevier Masson SAS. All rights reserved.
AP2238 was the first compound published to bind both anionic sites of the human acetylcholinesterase, allowing the simultaneous inhibition of the catalytic and the amyloid-beta pro-aggregating activities of AChE. Here we attempted to derive a comprehensive structure-activity relationship picture for this molecule, affording 28 derivatives for which AChE and BChE inhibitory activities were evaluated. Selected compounds were also tested for their ability to prevent the AChE-induced A beta-aggregation. Moreover, docking simulations and molecular orbital calculations were performed.
Synthesis of novel 4,6-diaryl-2-aminopyrimidines as potential antiplasmodial agents
作者:Rajani Giridhar、Riyaj S. Tamboli、Dhaval G. Prajapati、Sanket Soni、Sarita Gupta、M. R. Yadav
DOI:10.1007/s00044-012-0328-z
日期:2013.7
A novel series of 4,6-diaryl-2-aminopyrimidines 8a-o has been synthesized and evaluated for in vitro antiplasmodial activity against Plasmodium falciparum. Out of the 15 compounds synthesized and tested, 6 compounds have shown IC50 values in the range of 1.61-9.53 mu g/mL. These compounds are several times more potent than chloroquine and quinine, the two standard drugs used for the purpose of comparison.